Naloxone Dosing — Opioid Reversal
Patient type
Route
Αναλυτικός οδηγός σύντομα
Εργαζόμαστε πάνω σε έναν ολοκληρωμένο εκπαιδευτικό οδηγό για τον Naloxone Dose Calculator. Ελέγξτε ξανά σύντομα για αναλυτικές εξηγήσεις, τύπους, παραδείγματα και συμβουλές ειδικών.
Naloxone (Narcan) is a pure opioid antagonist that competitively binds to mu, kappa, and delta opioid receptors in the central and peripheral nervous system, reversing the effects of opioid agonists including respiratory depression, sedation, miosis, and analgesia. It has no agonist activity of its own and is inactive in the absence of opioids. Naloxone is the cornerstone of emergency treatment for opioid toxidrome and opioid overdose — one of the leading causes of preventable death in many countries. The drug has a short half-life of 30–90 minutes, which is significantly shorter than most opioids of abuse (heroin, fentanyl, methadone, buprenorphine, codeine), meaning re-narcotisation (recurrence of opioid effects after naloxone wears off) is a major clinical risk that must be anticipated. Dosing is by titration to clinical effect rather than a fixed dose, with the goal of restoring adequate spontaneous ventilation (respiratory rate >10–12/min) while avoiding precipitating acute opioid withdrawal, which causes profound distress, agitation, vomiting, hypertension, and seizures in opioid-dependent patients. Intravenous naloxone can be given at 0.4–2 mg per dose, repeated every 2–3 minutes as needed. Intramuscular naloxone 0.8 mg is the standard community dose in many take-home naloxone programmes. Intranasal naloxone 4 mg per nostril has become widely available as a community rescue medication (Narcan nasal spray) requiring no medical training to administer. Intravenous infusion at two-thirds of the effective reversal dose per hour is used for sustained reversal of long-acting opioids such as methadone.
IV: 0.4–2 mg titrated q2–3 min; IM: 0.8 mg; Intranasal: 4 mg; IV infusion = (2/3 × reversal bolus dose) mg/h
- 1Step 1 — Identify opioid toxidrome: Classic triad of decreased consciousness (GCS ≤12), respiratory depression (RR <10/min or SpO2 <90%), and miosis (pinpoint pupils). Other features: bradycardia, hypothermia, decreased bowel sounds.
- 2Step 2 — Secure airway and oxygenate: Apply high-flow oxygen via non-rebreather mask or assist ventilation with bag-mask device before administering naloxone to prevent hypoxic cardiac arrest during the response window.
- 3Step 3 — Establish IV access (if available): Administer naloxone 0.4–0.8 mg IV (lower dose in opioid-dependent patients to avoid precipitating withdrawal). If no IV access, use IM 0.8 mg into anterolateral thigh.
- 4Step 4 — Titrate to respiratory response: Wait 2–3 minutes after each dose. Goal is restoration of adequate ventilation (RR >10–12/min), NOT full consciousness. Avoid over-dosing — full reversal causes acute withdrawal.
- 5Step 5 — Repeat doses: Continue 0.4 mg IV every 2–3 minutes up to a total of 10 mg if no response. No response after 10 mg challenges the diagnosis of opioid toxidrome.
- 6Step 6 — Consider IV infusion for long-acting opioids: For methadone, slow-release morphine, fentanyl patches — calculate infusion at 2/3 of the effective bolus dose per hour in 5% dextrose; reassess hourly.
- 7Step 7 — Monitor for re-narcotisation: Observe for minimum 4 hours after last naloxone dose in short-acting opioid overdose; 12–24 hours for long-acting opioids (methadone). Discharge only when opioid effect has clearly resolved.
Start low if opioid dependence suspected to avoid precipitating severe withdrawal
Heroin half-life ~30 min; naloxone 30–90 min. One dose may suffice for short-acting opioids. Monitor 4h post last dose. If RR improves, hold further doses.
Illicit fentanyl and carfentanil are highly potent and may require 5–10x standard naloxone dose
Fentanyl is 100× more potent than morphine. Street fentanyl mixtures may include carfentanil (10,000× potency). Standard 0.4–0.8 mg doses are often insufficient. Intranasal 4 mg per nostril is now standard community recommendation.
Methadone half-life 24–36h; naloxone infusion mandatory to prevent re-narcotisation
Methadone half-life far exceeds naloxone. Without infusion, patient will re-narcotise as naloxone wears off. Run infusion at 2/3 of effective reversal dose per hour and titrate.
Use smallest effective dose to maintain analgesia; full reversal will cause severe pain and cardiovascular stress
In opioid-naive post-op patients, very low doses (40–100 mcg increments) are effective and avoid acute pain crisis from full reversal. Target RR >10/min, adequate SpO2.
Emergency department and pre-hospital reversal of opioid overdose respiratory depression, representing an important application area for the Naloxone Dose in professional and analytical contexts where accurate naloxone dose calculations directly support informed decision-making, strategic planning, and performance optimization
Post-operative recovery room management of opioid-induced respiratory depression after anaesthesia, representing an important application area for the Naloxone Dose in professional and analytical contexts where accurate naloxone dose calculations directly support informed decision-making, strategic planning, and performance optimization
Community take-home naloxone programmes providing lay bystander rescue treatment for overdose, representing an important application area for the Naloxone Dose in professional and analytical contexts where accurate naloxone dose calculations directly support informed decision-making, strategic planning, and performance optimization
Opioid treatment programmes (methadone clinics) for supervised naloxone administration in high-risk patients, representing an important application area for the Naloxone Dose in professional and analytical contexts where accurate naloxone dose calculations directly support informed decision-making, strategic planning, and performance optimization
Intraoperative reversal of inadvertent excessive opioid dosing during regional anaesthesia or procedural sedation, representing an important application area for the Naloxone Dose in professional and analytical contexts where accurate naloxone dose calculations directly support informed decision-making, strategic planning, and performance optimization
Illicit Fentanyl and Novel Synthetic Opioids
{'title': 'Illicit Fentanyl and Novel Synthetic Opioids', 'body': 'Street fentanyl and its analogues (carfentanil, acetylfentanyl) are 100–10,000 times more potent than morphine. Standard naloxone doses are often insufficient. Multiple doses of intranasal naloxone (up to 4 sprays, 16 mg total) may be required. Community programmes now recommend 4 mg intranasal as the starting dose rather than 2 mg for all suspected fentanyl overdoses.'}
Methadone and Long-Acting Opioids
{'title': 'Methadone and Long-Acting Opioids', 'body': 'Methadone has a half-life of 24–36 hours and can cause delayed respiratory depression many hours after ingestion. All suspected methadone overdoses require hospital admission and 12–24h observation regardless of initial response to naloxone. An IV infusion of naloxone is almost always required. Morphine slow-release capsule overdoses should be managed similarly.'}
Neonatal Opioid Exposure
{'title': 'Neonatal Opioid Exposure', 'body': 'Neonates born to mothers on opioid maintenance therapy or who used heroin near delivery may present with respiratory depression. Naloxone 0.01 mg/kg IV/IM/umbilical is used for neonates. Avoid in infants of opioid-dependent mothers if possible as it precipitates neonatal withdrawal seizures. Supportive ventilation is preferred over naloxone in neonates of opioid-dependent mothers.'}
Opioid Overdose in Palliative Care
{'title': 'Opioid Overdose in Palliative Care', 'body': "In end-of-life care, naloxone administration must be balanced against the patient's goals and the cause of sedation. If respiratory depression is due to opioid accumulation (renal failure, dose escalation) rather than overdose intent, low-dose titrated naloxone may restore ventilation without precipitating pain crisis. Family goals of care discussions are essential before administration."}
Combined Drug Overdose
{'title': 'Combined Drug Overdose', 'body': 'Opioid overdose frequently co-occurs with benzodiazepines, alcohol, or stimulants. Naloxone reverses only the opioid component. Residual sedation may persist after naloxone from benzodiazepines (no specific antidote — supportive care). Combined opioid-benzo overdose has higher mortality. Flumazenil (benzodiazepine antagonist) is rarely used due to seizure risk in mixed overdose.'}
| Route | Dose | Onset | Duration | Context |
|---|---|---|---|---|
| IV (standard) | 0.4–2 mg q2–3 min | 1–2 min | 30–90 min | Hospital, IV access available |
| IV (low-dose) | 0.04–0.1 mg increments | 1–2 min | 30–60 min | Opioid-dependent, post-op reversal |
| IV infusion | 2/3 reversal dose per hour | Continuous | Ongoing | Long-acting opioids (methadone) |
| IM | 0.8 mg (anterolateral thigh) | 5–10 min | 45–90 min | No IV access, community response |
| Intranasal | 4 mg per nostril | 5–10 min | 45–90 min | Community rescue, no needles |
| SC | 0.4–0.8 mg | 10–15 min | 30–90 min | Slow reversal in palliative care |
Why does naloxone wear off before the opioid?
Naloxone has a plasma half-life of 30–90 minutes, which is shorter than most opioids including heroin (1–4h), morphine (2–4h), methadone (24–36h), and fentanyl patches (16–24h). As naloxone is metabolised faster than the opioid, opioid receptor occupancy resumes and the patient can re-narcotise — fall back into respiratory depression. This is the primary reason for mandatory observation periods.
What is re-narcotisation and how do you prevent it?
Re-narcotisation is the recurrence of opioid respiratory depression after naloxone effect wears off. Prevention involves: minimum 4-hour observation after last naloxone dose (short-acting opioids), 12–24 hours observation for long-acting opioids, IV infusion maintenance for methadone/slow-release overdoses, and hospital admission for all methadone and fentanyl patch overdoses. This is particularly important in the context of naloxone dose calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise naloxone dose computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
What is precipitated withdrawal and how do you avoid it?
In opioid-dependent patients, administering naloxone at high doses causes acute opioid withdrawal — a sudden, severe syndrome including agitation, vomiting, diarrhoea, hypertension, tachycardia, seizures, and extreme distress. Avoid by starting with small doses (0.04–0.1 mg IV) and titrating to ventilation only. The goal is NOT full consciousness — it is adequate spontaneous breathing.
Is naloxone safe in pregnancy?
Naloxone is generally safe in pregnancy and is indicated for maternal opioid overdose. However, it may precipitate acute fetal withdrawal and distress by crossing the placenta. The risk of maternal respiratory arrest from untreated opioid overdose far outweighs the risk to the fetus, so naloxone should be administered without hesitation in maternal overdose.
Can naloxone be given subcutaneously?
Yes, subcutaneous (SC) naloxone can be used but has slower and more variable absorption than IM injection. IM injection into the anterolateral thigh (through clothing if necessary) achieves faster and more reliable absorption and is preferred when IV access is unavailable. SC is sometimes used in palliative care settings for slow reversal of opioid side effects.
What if there is no response to 10 mg of naloxone?
Failure to respond to 10 mg of naloxone (equivalent to 25 doses of 0.4 mg) should prompt reconsideration of the diagnosis. Alternative causes of coma should be investigated: hypoglycaemia, TCA overdose, benzodiazepines (no reversal with naloxone), head injury, stroke, or sepsis. Naloxone does not reverse benzodiazepine toxicity — flumazenil is the benzodiazepine antagonist.
What is take-home naloxone?
Take-home naloxone (THN) programmes provide naloxone kits (IM auto-injectors or intranasal spray) directly to people who use opioids and their families or friends. Bystanders can administer it before emergency services arrive, significantly reducing opioid overdose mortality. UK, USA, Canada, and Australia all have established THN programmes. Lay administration does not require medical training.
Does naloxone reverse buprenorphine overdose?
Buprenorphine (Subutex/Suboxone) is a partial opioid agonist with very high receptor affinity. Pure buprenorphine overdose is relatively uncommon because its ceiling effect limits respiratory depression, but in combination with benzodiazepines or alcohol it can be fatal. Higher doses of naloxone (2–4 mg IV) are required to overcome buprenorphine's receptor affinity, and repeat dosing is often needed.
Pro Tip
Remember the '2/3 rule' for naloxone infusion: once you find the IV dose that reverses respiratory depression (e.g., 2 mg), run an hourly infusion at 2/3 of that dose (e.g., 1.33 mg/h) diluted in 5% dextrose. Reassess every 30–60 minutes and adjust. This is the minimum required to prevent re-narcotisation with long-acting opioids.
Did you know?
Naloxone was first synthesised in 1960 by Jack Fishman and Mozes Lewenstein at Endo Laboratories, New York. It was initially studied as a potential analgesic (it failed — it blocked all pain relief too). Its value as an antidote was recognised shortly after, and it was approved for opioid reversal in 1971. Now, over 50 years later, community take-home naloxone programmes have prevented tens of thousands of overdose deaths worldwide.